Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed by your doctor with moderate to severe rheumatoid arthritis (RA) that is currently active, or you have had this diagnosis in the past.
- Your doctor has already independently decided to prescribe you either Upadacitinib or a TNF inhibitor (a type of biologic medication for RA) before you were considered for this study.
- The medication prescribed to you (Upadacitinib or TNF inhibitor) is being used in the standard, approved way according to official guidelines in your country.
Who may not be able to join:
- You have taken part in another clinical trial using an experimental drug recently (within the last 30 days, or longer depending on the drug used — confirm with trial site).
- You have previously been treated with Upadacitinib at any point in the past.
- You have previously been treated with the same TNF inhibitor medication that your doctor is now planning to prescribe for this study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 49 611 1720 1520
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Retention Rate of UPA vs TNFi
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.